Skip to main content

INNOVEN: Efficacy of Porcine Placental Extracellular Matrix Plus Standard of Care (SOC) Versus SOC Alone

Recruiting · Not applicable · NCT06606210

Conditions: Wound Heal, Venous Leg Ulcer

At a glance

Research payments reported, 2025
$752,327
U.S. investigators named
7
Sites paid
8
Planned or actual enrollment
120

About the trial

Sponsor
ConvaTec Inc.
Tested
InnovaMatrix® AC (device)
Dates
Started 2024-09-19; completion 2026-04
Results posted
Not yet

INNOVEN is a multi-center randomized controlled clinical trial to evaluate the efficacy of porcine placental extracellular matrix (PPECM) and standard of care (SOC) versus SOC alone in the closure of non-healing venous leg ulcers (VLUs).

From ClinicalTrials.gov, last updated 2025-08-22. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Convatec Inc. reported $752,327 in research payments for this study in 2025 (70 payments).

Products named: Innovamatrix Ac

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Wound Centrics LLC $218,990
  • Wound Care of Tulsa $145,660
  • Wahab Consulting and Research LLC $116,905
  • Symphony Research $110,262
  • Clinical Research Management Group $69,175
  • Valiance Clinical Research Northridge $44,060
  • Valiance Clinical Res $30,225
  • Three Rivers Wound and Hyberbaric Center $17,050

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.